Semaglutide

Semaglutide is a molecule used in drugs like Wegovy and Ozempic, manufactured by Novo Nordisk, primarily for weight loss and type 2 diabetes treatment. It's a GLP-1 receptor agonist that lowers blood sugar and slows digestion. Semaglutide is newsworthy due to several recent developments. Firstly, the patent on semaglutide is expiring in India, potentially leading to cheaper, generic versions and reshaping the global obesity fight. Secondly, alternative GLP-1 medications, like orforglipron by Eli Lilly, are being developed as oral alternatives, showing promising weight loss results in trials. Finally, regulators in the UK are issuing warnings about a small risk of severe acute pancreatitis associated with weight-loss jabs like semaglutide, highlighting potential safety concerns. The drug's increasing popularity and these developments make it a significant topic in healthcare.